{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:23:02Z","timestamp":1793211782511,"version":"4.5.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DA041359"],"award-info":[{"award-number":["R01 DA041359"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DA056581"],"award-info":[{"award-number":["R01 DA056581"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DA013429"],"award-info":[{"award-number":["P30DA013429"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.pbb.2025.174056","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:13:16Z","timestamp":1751422396000},"page":"174056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["KOR agonists for the treatment and\/or prevention of opioid use disorder and cocaine use disorder"],"prefix":"10.1016","volume":"254","author":[{"given":"Lee-Yuan","family":"Liu-Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2025.174056_bb0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/np300697k","article-title":"The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior","volume":"76","author":"Aldrich","year":"2013","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.pbb.2025.174056_bb0010","first-page":"1","article-title":"Ibogaine: a review","volume":"56","author":"Alper","year":"2001","journal-title":"Alkaloids Chem. Biol."},{"key":"10.1016\/j.pbb.2025.174056_bb0015","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/105504999305848","article-title":"Treatment of acute opioid withdrawal with ibogaine","volume":"8","author":"Alper","year":"1999","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.pbb.2025.174056_bb0020","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.neuropharm.2019.02.010","article-title":"MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats","volume":"150","author":"Atigari","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0025","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00213-005-0167-4","article-title":"Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats","volume":"183","author":"Beardsley","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0030","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00213-010-1846-3","volume":"210","author":"Beardsley","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0035","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fphar.2020.00188","article-title":"Functional selectivity and antinociceptive effects of a novel KOPr agonist","volume":"11","author":"Bedini","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(96)00698-X","article-title":"Effects of the kappa-opioid receptor agonist U-50,488 on morphine-induced place preference conditioning in the developing rat","volume":"317","author":"Bolanos","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0045","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/sj.npp.1300105","article-title":"Effects of mixed-action kappa\/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys","volume":"28","author":"Bowen","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brainres.2009.08.062","article-title":"The dynorphin\/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors","volume":"1314","author":"Bruchas","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.pbb.2025.174056_bb0055","doi-asserted-by":"crossref","first-page":"ra117","DOI":"10.1126\/scisignal.aai8441","article-title":"Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria","volume":"9","author":"Brust","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.pbb.2025.174056_bb0060","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1038\/npp.2015.27","article-title":"A double-blind, placebo-controlled trial to evaluate the safety, tolerability, and pharmacokinetics of single, escalating oral doses of JDTic","volume":"40","author":"Buda","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0065","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1021\/acschemneuro.0c00407","article-title":"Comparison of pharmacological properties between the kappa opioid receptor agonist nalfurafine and 42B, its 3-dehydroxy analogue: disconnect between in vitro agonist bias and in vivo pharmacological effects","volume":"11","author":"Cao","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pbb.2025.174056_bb0070","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1021\/jm301783x","article-title":"Development of kappa opioid receptor antagonists","volume":"56","author":"Carroll","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2025.174056_bb0075","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/npp.2015.258","article-title":"Dynorphin, dysphoria, and dependence: the stress of addiction","volume":"41","author":"Chavkin","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0080","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0306-4522(00)00417-6","article-title":"Kappa-opioid receptor activation prevents alterations in mesocortical dopamine neurotransmission that occur during abstinence from cocaine","volume":"101","author":"Chefer","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2025.174056_bb0085","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1038\/npp.2013.171","article-title":"Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion","volume":"38","author":"Chefer","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0090","article-title":"Agonist-promoted phosphorylation and internalization of the kappa opioid receptor in mouse brains: lack of connection with conditioned place aversion","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0165-6147(90)90322-Y","article-title":"Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. [review]","volume":"11","author":"Crain","year":"1990","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2025.174056_bb0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0304-3940(00)01593-7","article-title":"Spinal kappa-opioid system plays an important role in suppressing morphine withdrawal syndrome in the rat","volume":"295","author":"Cui","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pbb.2025.174056_bb0105","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1021\/acschemneuro.9b00195","article-title":"Signaling properties of structurally diverse kappa opioid receptor ligands: toward in vitro models of in vivo responses","volume":"10","author":"Dunn","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pbb.2025.174056_bb0110","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1007\/s00213-020-05543-7","article-title":"Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice","volume":"237","author":"Dunn","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0115","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/bph.12132","article-title":"The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting kappa opioid receptor antagonism in the CNS after oral administration","volume":"169","author":"Eans","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0120","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0022-3565(25)20761-3","article-title":"Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor","volume":"278","author":"Emmerson","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2025.174056_bb0125","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0024-3205(99)00417-8","article-title":"Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist","volume":"65","author":"Endoh","year":"1999","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2025.174056_bb0130","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00213-017-4637-2","article-title":"The C-2 derivatives of salvinorin A, ethoxymethyl ether Sal B and beta-tetrahydropyran Sal B, have anti-cocaine properties with minimal side effects","volume":"234","author":"Ewald","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0135","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pbb.2025.174056_bb0140","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1021\/cn200128x","article-title":"Discovery of small molecule kappa opioid receptor agonist and antagonist chemotypes through a HTS and hit refinement strategy","volume":"3","author":"Frankowski","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pbb.2025.174056_bb0145","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s00213-014-3436-2","article-title":"Assessment of the kappa opioid agonist, salvinorin a, as a punisher of drug self-administration in monkeys","volume":"231","author":"Freeman","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/add.16318","article-title":"Charting the fourth wave: geographic, temporal, race\/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-2021","author":"Friedman","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.pbb.2025.174056_bb0155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0014-2999(89)90132-5","article-title":"Effects of a selective kappa-opioid agonist, U-50,488H, on morphine dependence in rats","volume":"170","author":"Fukagawa","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0160","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/0028-3908(93)90026-Y","article-title":"Blockade of morphine reward through the activation of kappa-opioid receptors in mice","volume":"32","author":"Funada","year":"1993","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0165","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00213-007-1067-6","article-title":"Effects of acute and repeated administration of salvinorin a on dopamine function in the rat dorsal striatum","volume":"197","author":"Gehrke","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0170","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0006-8993(95)00306-B","article-title":"Kappa opioid inhibition of morphine and cocaine self-administration in rats","volume":"681","author":"Glick","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.pbb.2025.174056_bb0175","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.neuron.2012.12.034","article-title":"Kappa opioid receptors regulate stress-induced cocaine seeking and synaptic plasticity","volume":"77","author":"Graziane","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.pbb.2025.174056_bb0180","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1196\/annals.1316.050","article-title":"Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence","volume":"1025","author":"Hasebe","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.pbb.2025.174056_bb0185","doi-asserted-by":"crossref","first-page":"8118","DOI":"10.1038\/s41467-024-51856-y","article-title":"Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models","volume":"15","author":"Havel","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pbb.2025.174056_bb0190","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0022-3565(25)12030-2","article-title":"Development of behavioral sensitization to cocaine: influence of kappa opioid receptor agonists","volume":"275","author":"Heidbreder","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2025.174056_bb0195","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.neuroimage.2008.03.003","article-title":"Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans","volume":"41","author":"Hooker","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.pbb.2025.174056_bb0200","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00213-020-05519-7","article-title":"Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys","volume":"237","author":"Huskinson","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173394","article-title":"The G-protein biased kappa opioid agonists, triazole 1.1 and nalfurafine, produce non-uniform behavioral effects in male rhesus monkeys","volume":"217","author":"Huskinson","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2025.174056_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.110953","article-title":"Quantification of observable behaviors following oral administration of oxycodone and nalfurafine in male rhesus monkeys","volume":"252","author":"Huskinson","year":"2023","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2025.174056_bb0215","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejphar.2004.09.010","article-title":"Kappa opioid agonists suppress chloroquine-induced scratching in mice","volume":"502","author":"Inan","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0220","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.drugalcdep.2010.11.005","article-title":"Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum","volume":"115","author":"Johnson","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2025.174056_bb0225","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12799","article-title":"A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior","volume":"25","author":"Jones","year":"2020","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pbb.2025.174056_bb0230","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/jpet.118.255661","article-title":"Preclinical testing of nalfurafine as an opioid-sparing adjuvant that potentiates analgesia by the mu opioid receptor-targeting agonist morphine","volume":"371","author":"Kaski","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2025.174056_bb0235","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neuropharm.2014.07.016","article-title":"Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1\/2-dependent mechanism","volume":"86","author":"Kivell","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23102602","article-title":"Kappa opioid receptor agonist Mesyl Sal B attenuates behavioral sensitization to cocaine with fewer aversive side-effects than salvinorin A in rodents","volume":"23","author":"Kivell","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.pbb.2025.174056_bb0245","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/jpet.108.143925","article-title":"Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates","volume":"328","author":"Ko","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2025.174056_bb0250","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biopsych.2019.05.023","article-title":"Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement","volume":"87","author":"Koob","year":"2020","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2025.174056_bb0255","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pharmrev.120.000083","article-title":"Drug addiction: hyperkatifeia\/negative reinforcement as a framework for medications development","volume":"73","author":"Koob","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pbb.2025.174056_bb0260","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/7854_2021_288","article-title":"Anhedonia, Hyperkatifeia, and negative reinforcement in substance use disorders","volume":"58","author":"Koob","year":"2022","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.pbb.2025.174056_bb0265","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/IJNRD.S145720","article-title":"Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch((R)) capsules 2.5 mug) in 3,762 hemodialysis patients with intractable pruritus","volume":"11","author":"Kozono","year":"2018","journal-title":"Int. J. Nephrol. Renov. Dis."},{"key":"10.1016\/j.pbb.2025.174056_bb0270","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.pbb.2025.174056_bb0275","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000341268","article-title":"Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients","volume":"36","author":"Kumagai","year":"2012","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.pbb.2025.174056_bb0280","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0014-2999(96)00961-2","article-title":"Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice","volume":"321","author":"Kuzmin","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0285","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1213\/00000539-199704000-00021","article-title":"Nalbuphine coadministered with morphine prevents tolerance and dependence","volume":"84","author":"Lee","year":"1997","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.pbb.2025.174056_bb0290","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/14656566.2020.1849142","article-title":"An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease","volume":"22","author":"Lipman","year":"2021","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.pbb.2025.174056_bb0295","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41386-018-0155-0","article-title":"Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in kappa opioid aversion","volume":"44","author":"Liu","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.964724","article-title":"Signaling underlying kappa opioid receptor-mediated behaviors in rodents","volume":"16","author":"Liu-Chen","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.pbb.2025.174056_bb0305","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00213-012-2912-9","article-title":"Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects","volume":"226","author":"MacLean","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0310","doi-asserted-by":"crossref","first-page":"8312","DOI":"10.1523\/JNEUROSCI.22-18-08312.2002","article-title":"Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity","volume":"22","author":"Mao","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2025.174056_bb0315","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0022-3565(24)37657-8","article-title":"Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys","volume":"286","author":"Mello","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2025.174056_bb0320","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1749-6632.2000.tb06678.x","article-title":"Interactions between kappa opioid agonists and cocaine. Preclinical studies","volume":"909","author":"Mello","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.pbb.2025.174056_bb0325","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/164_2020_400","article-title":"Clinical profiles of nalfurafine hydrochloride for the treatment of pruritus patients","volume":"271","author":"Miyamoto","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0330","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pbb.2009.09.002","article-title":"Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats","volume":"94","author":"Morani","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2025.174056_bb0335","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/FBP.0b013e3283512c1e","article-title":"A single injection of a novel kappa opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats","volume":"23","author":"Morani","year":"2012","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0340","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejphar.2013.10.050","article-title":"The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats","volume":"720","author":"Morani","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0345","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00213-002-1028-z","article-title":"Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats","volume":"161","author":"Mori","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0350","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bmc.2007.10.067","article-title":"Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers","volume":"16","author":"Munro","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.pbb.2025.174056_bb0355","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1248\/cpb.46.366","article-title":"Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan","volume":"46","author":"Nagase","year":"1998","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.pbb.2025.174056_bb0360","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0024-3205(93)90153-T","article-title":"Blockade of the morphine-induced increase in turnover of dopamine on the mesolimbic dopaminergic system by kappa-opioid receptor activation in mice","volume":"52","author":"Narita","year":"1993","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2025.174056_bb0365","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s00213-004-1878-7","article-title":"Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys","volume":"176","author":"Negus","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0370","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0022-3565(24)36769-2","article-title":"Effects of kappa opioids on cocaine self-administration by rhesus monkeys","volume":"282","author":"Negus","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2025.174056_bb0375","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1037\/a0013088","article-title":"Mu\/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability","volume":"16","author":"Negus","year":"2008","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0380","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.biopsych.2005.09.018","article-title":"The mesolimbic dopamine reward circuit in depression","volume":"59","author":"Nestler","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2025.174056_bb0385","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0165-6147(98)01169-9","article-title":"mu-Opposing actions of the kappa-opioid receptor","volume":"19","author":"Pan","year":"1998","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2025.174056_bb0390","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00002826-199619050-00009","article-title":"Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain","volume":"19","author":"Pande","year":"1996","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0395","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by kappa opiate receptors","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.pbb.2025.174056_bb0400","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1039\/c1md00192b","article-title":"Potential drug abuse therapeutics derived from the hallucinogenic natural product salvinorin A","volume":"2","author":"Prevatt-Smith","year":"2011","journal-title":"Medchemcomm"},{"key":"10.1016\/j.pbb.2025.174056_bb0405","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/npp.2017.245","article-title":"Repeated administration of opra kappa (LY2456302), a novel, short-acting, selective KOP-r antagonist, in persons with and without cocaine dependence","volume":"43","author":"Reed","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0410","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/164_2020_401","article-title":"Kappa opioid receptor antagonists as potential therapeutics for mood and substance use disorders","volume":"271","author":"Reed","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0415","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1124\/molpharm.120.000124","article-title":"Regulation of kappa opioid receptor inactivation depends on sex and cellular site of antagonist action","volume":"98","author":"Reichard","year":"2020","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0420","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/AAP.0000000000000326","article-title":"Effects of intrathecal kappa-opioid receptor agonist on morphine-induced itch and antinociception in mice","volume":"41","author":"Sakakihara","year":"2016","journal-title":"Reg. Anesth. Pain Med."},{"key":"10.1016\/j.pbb.2025.174056_bb0425","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellsig.2017.01.016","article-title":"Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor","volume":"32","author":"Schattauer","year":"2017","journal-title":"Cell. Signal."},{"key":"10.1016\/j.pbb.2025.174056_bb0430","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s002130051016","article-title":"U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking","volume":"144","author":"Schenk","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0435","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0893-133X(00)00190-1","article-title":"Effects of the kappa-opioid receptor agonist, U69593, on the development of sensitization and on the maintenance of cocaine self-administration","volume":"24","author":"Schenk","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0440","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0022-3565(24)37462-2","article-title":"Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus","volume":"285","author":"Selley","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2025.174056_bb0445","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0022-3565(25)12305-7","article-title":"Kappa-opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine","volume":"276","author":"Shippenberg","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2025.174056_bb0450","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1749-6632.2001.tb03558.x","article-title":"Modulation of the behavioral and neurochemical effects of psychostimulants by kappa-opioid receptor systems","volume":"937","author":"Shippenberg","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.pbb.2025.174056_bb0455","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jep.2008.01.029","article-title":"The comparison of effects of processed Aconiti tuber, U50488H and MK-801 on the antinociceptive tolerance to morphine","volume":"117","author":"Shu","year":"2008","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0460","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bph.12692","article-title":"Pharmacology and anti-addiction effects of the novel kappa opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin a","volume":"172","author":"Simonson","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0465","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.neuron.2018.08.044","article-title":"Kappa opioid receptor distribution and function in primary afferents","volume":"99","author":"Snyder","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.pbb.2025.174056_bb0470","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/164_2020_431","article-title":"Kappa opioid receptor ligands and pharmacology: diphenethylamines, a class of structurally distinct, selective kappa opioid ligands","volume":"271","author":"Spetea","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0475","doi-asserted-by":"crossref","DOI":"10.1111\/bph.13854","article-title":"Selective kappa opioid receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice","author":"Spetea","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0480","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejphar.2004.10.051","article-title":"Effects of the mixed-action kappa\/mu opioid agonist 8-carboxamidocyclazocine on cocaine- and food-maintained responding in rhesus monkeys","volume":"506","author":"Stevenson","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0485","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0021-5198(19)39723-9","article-title":"The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference","volume":"58","author":"Suzuki","year":"1992","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0490","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0014-2999(97)00062-9","article-title":"Differential effects of mu-, delta- and kappa-opioid receptor agonists on the discriminative stimulus properties of cocaine in rats","volume":"324","author":"Suzuki","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0495","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0014-2999(94)90553-3","article-title":"U-50,488 blocks the development of morphine tolerance and dependence at a very low dose in guinea pigs","volume":"256","author":"Tao","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0500","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/PL00004944","article-title":"The role of vasopressin on the effect of U-50,488 to block the development of morphine tolerance and physical dependence","volume":"355","author":"Tao","year":"1997","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0505","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.drugalcdep.2006.01.013","article-title":"Nalbuphine is effective in decreasing the rewarding effect induced by morphine in rats","volume":"84","author":"Tao","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2025.174056_bb0510","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ejpb.2009.01.002","article-title":"Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen","volume":"72","author":"Teksin","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.pbb.2025.174056_bb0515","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0014-2999(01)01588-6","article-title":"Antipruritic activity of the kappa-opioid receptor agonist, TRK-820","volume":"435","author":"Togashi","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0520","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1007\/s00213-017-4652-3","article-title":"Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats","volume":"234","author":"Townsend","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/S0024-3205(00)00582-8","article-title":"A novel kappa-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice","volume":"66","author":"Tsuji","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2025.174056_bb0530","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0014-2999(00)00139-4","article-title":"The novel kappa-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice","volume":"394","author":"Tsuji","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0535","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/S0024-3205(01)00957-2","article-title":"The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice","volume":"68","author":"Tsuji","year":"2001","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2025.174056_bb0540","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejphar.2003.08.007","article-title":"Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system","volume":"477","author":"Umeuchi","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0545","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s00213-017-4647-0","article-title":"Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats","volume":"234","author":"Valenza","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0550","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00213-019-05444-4","article-title":"Effects of kappa opioid receptor blockade by LY2444296 HCl, a selective short-acting antagonist, during chronic extended access cocaine self-administration and re-exposure in rat","volume":"237","author":"Valenza","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0555","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28124848","article-title":"The kappa opioid receptor agonist 16-bromo salvinorin A has anti-cocaine effects without significant effects on locomotion, food reward, learning and memory, or anxiety and depressive-like behaviors","volume":"28","author":"van de Wetering","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.pbb.2025.174056_bb0560","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/acschemneuro.5b00153","article-title":"Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior","volume":"6","author":"V\u00e1radi","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pbb.2025.174056_bb0565","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1399-6576.1997.tb04806.x","article-title":"Interaction between sufentanil and U-50488H with respect to antinociception and respiratory depression in rats","volume":"41","author":"Verborgh","year":"1997","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.pbb.2025.174056_bb0570","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1016\/j.lfs.2004.05.033","article-title":"Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys","volume":"75","author":"Wakasa","year":"2004","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2025.174056_bb0575","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s002130100788","article-title":"Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans","volume":"157","author":"Walsh","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0580","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1124\/jpet.104.073668","article-title":"Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo","volume":"312","author":"Wang","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2025.174056_bb0585","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1124\/jpet.107.132142","article-title":"2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin A","volume":"324","author":"Wang","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2025.174056_bb0590","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1124\/jpet.108.142802","volume":"329","author":"Wang","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2025.174056_bb0595","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1124\/jpet.114.216820","article-title":"The G protein-biased kappa-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo","volume":"352","author":"White","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2025.174056_bb0600","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0022-3565(24)37186-1","article-title":"Dopamine release in the nucleus accumbens during heroin self-administration is modulated by kappa opioid receptors: an in vivo fast-cyclic voltammetry study","volume":"284","author":"Xi","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2025.174056_bb0605","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.1021\/bi900605n","article-title":"Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor","volume":"48","author":"Yan","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.pbb.2025.174056_bb0610","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/brain\/awae106","article-title":"Tiam1-mediated maladaptive plasticity underlying morphine tolerance and hyperalgesia","volume":"147","author":"Yao","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.pbb.2025.174056_bb0615","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00213-020-05473-4","article-title":"Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys","volume":"237","author":"Zamarripa","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0620","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/FBP.0000000000000581","article-title":"The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone\u2019s conditioned rewarding effects in male rats","volume":"31","author":"Zamarripa","year":"2020","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0625","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1007\/s00213-021-05965-x","article-title":"The kappa-opioid receptor agonist, triazole 1.1, reduces oxycodone self-administration and enhances oxycodone-induced thermal antinociception in male rats","volume":"238","author":"Zamarripa","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0630","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00213-023-06486-5","article-title":"Contingent administration of typical and biased kappa opioid agonists reduces cocaine and oxycodone choice in a drug vs. food choice procedure in male rhesus monkeys","volume":"241","author":"Zamarripa","year":"2024","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108244","article-title":"Nalfurafine modulates the reinforcing effects of oxycodone in male and female adolescent C57BL\/6J mice","volume":"176","author":"Zhang","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2025.174056_bb0640","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1499799","article-title":"Microglia in morphine tolerance: cellular and molecular mechanisms and therapeutic potential","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146410","article-title":"Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice","volume":"1724","author":"Zhou","year":"2019","journal-title":"Brain Res."},{"key":"10.1016\/j.pbb.2025.174056_bb0650","doi-asserted-by":"crossref","first-page":"36703","DOI":"10.1074\/jbc.M113.504381","article-title":"Development of functionally selective, small molecule agonists at kappa opioid receptors","volume":"288","author":"Zhou","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pbb.2025.174056_bb0655","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3892\/etm.2021.10437","article-title":"Molecular mechanisms of opioid tolerance: from opioid receptors to inflammatory mediators (review)","volume":"22","author":"Zhou","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.pbb.2025.174056_bb0660","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/164_2021_443","article-title":"Preclinical studies on nalfurafine (TRK-820), a clinically used KOR agonist","volume":"271","author":"Zhou","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.pbb.2025.174056_bb0665","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0022-3565(24)36877-6","article-title":"Activation of the cloned human k opioid receptor by agonists enhances [35S]GTPgS binding to membranes: determination of potencies and efficacies of ligands","volume":"282","author":"Zhu","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305725001030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305725001030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:46:45Z","timestamp":1776919605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305725001030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":133,"alternative-id":["S0091305725001030"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2025.174056","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KOR agonists for the treatment and\/or prevention of opioid use disorder and cocaine use disorder","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2025.174056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"174056"}}